Human Microbiome Market (5th Edition): Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Product, Type of Biologic, Route of Administration, Drug Formulation, Target Indication, Target Therapeutic Area and Geographical Regions

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2.1. Chapter Overview
2.2. Research Assumptions
2.2.1. Market Landscape and Market Trends
2.2.2. Market Forecast and Opportunity Analysis
2.2.3. Comparative Analysis
2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis
2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources
2.4.2. Primary Research
2.4.2.1. Types of Primary Research
2.4.2.1.1. Qualitative Research
2.4.2.1.2. Quantitative Research
2.4.2.1.3. Hybrid Approach
2.4.2.2. Advantages of Primary Research
2.4.2.3. Techniques for Primary Research
2.4.2.3.1. Interviews
2.4.2.3.2. Surveys
2.4.2.3.3. Focus Groups
2.4.2.3.4. Observational Research
2.4.2.3.5. Social Media Interactions
2.4.2.4. Key Opinion Leaders Considered in Primary Research
2.4.2.4.1. Company Executives (CXOs)
2.4.2.4.2. Board of Directors
2.4.2.4.3. Company Presidents and Vice Presidents
2.4.2.4.4. Research and Development Heads
2.4.2.4.5. Technical Experts
2.4.2.4.6. Subject Matter Experts
2.4.2.4.7. Scientists
2.4.2.4.8. Doctors and Other Healthcare Providers
2.4.2.5. Ethics and Integrity
2.4.2.5.1. Research Ethics
2.4.2.5.2. Data Integrity
2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3.1. Chapter Overview
3.2. Forecast Methodology
3.2.1. Top-down Approach
3.2.2. Bottom-up Approach
3.2.3. Hybrid Approach
3.3. Market Assessment Framework
3.3.1. Total Addressable Market (TAM)
3.3.2. Serviceable Addressable Market (SAM)
3.3.3. Serviceable Obtainable Market (SOM)
3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
3.4.1. Qualitative Forecasting
3.4.2. Correlation
3.4.3. Regression
3.4.4. Extrapolation
3.4.5. Convergence
3.4.6. Sensitivity Analysis
3.4.7. Scenario Planning
3.4.8. Data Visualization
3.4.9. Time Series Analysis
3.4.10. Forecast Error Analysis
3.5. Key Considerations
3.5.1. Demographics
3.5.2. Government Regulations
3.5.3. Reimbursement Scenarios
3.5.4. Market Access
3.5.5. Supply Chain
3.5.6. Industry Consolidation
3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4.1. Chapter Overview
4.2. Market Dynamics
4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates
4.2.2. Currency Coverage
4.2.2.1. Major Currencies Affecting the Market
4.2.2.2. Factors Affecting Currency Fluctuations
4.2.2.3. Impact of Currency Fluctuations on the Industry
4.2.3. Foreign Currency Exchange Rate
4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
4.2.4. Recession
4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on Market Evolution
4.2.6. Interest Rates
4.2.6.1. Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk
4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation
4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario
4.2.8.3. Trade Policies
4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
4.2.8.5. Impact of Trade Barriers on the Market
4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War
4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies
4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. Stock Market Performance
4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6.1. Chapter Overview
6.2. Concept of Microbiota and Microbiome
6.2.1. Discovery of Human Microbiome
6.2.2. Functions of Human Microbiome
6.3. Overview of Gut Flora
6.3.1. Role of Gut Flora in Human Health
6.3.2. Factors Affecting Gut Flora
6.3.2.1. Antibiotic Consumption
6.3.2.2. Age and Pregnancy
6.3.2.2.1. Mode of Childbirth
6.3.2.2.2. Type of Feeding
6.3.2.2.3. Antibiotic Consumption by Mother
6.3.2.3. Stress-related Factors
6.3.2.4. Dietary Factors
6.3.2.5. Impact of Lifestyle
6.4. Microbiome and Associated Diseases
6.4.1. Cancer
6.4.2. Inflammatory Bowel Disease (IBD)
6.4.3. Obesity
6.4.4. Parkinson’s Disease
6.4.5. Type 2 Diabetes
6.4.6. Other Disease Indications
6.5. Impact of Microbiota on Drug Pharmacokinetics
6.6. Impact of Microbiota on Therapeutic Outcomes
6.7. Microbiome Therapeutics
6.7.1. Probiotics
6.7.1.1. Beneficial Bacterial Strains
6.7.1.1.1. Lactobacilli
6.7.1.1.2. Bifidobacteria
6.7.1.1.3. Others
6.7.1.2. Key Therapeutic Areas
6.7.1.2.1. Antibiotic-Associated Diarrhea (AAD)
6.7.1.2.2. Bacterial Vaginosis
6.7.1.2.3. High Blood Pressure
6.7.1.2.4. Hypercholesterolemia
6.7.1.2.5. Infectious Childhood Diarrhea (ICD)
6.7.1.2.6. Inflammatory Bowel Disease (IBD)
6.7.1.2.7. Lactose Intolerance
6.7.1.2.8. Vitamin Production
6.7.1.2.9. Weight Management
6.7.1.3. Side Effects of Probiotics
6.7.2. Prebiotics
6.7.2.1. Sources of Prebiotics
6.7.2.2. Types of Prebiotics
6.7.2.2.1. Fructo-Oligosaccharides (FOS)
6.7.2.2.2. Galacto-Oligosaccharides (GOS)
6.7.2.2.3. Inulin
6.7.2.3. Key Therapeutic Areas
6.7.2.3.1. Antibiotic Associated Diarrhea (AAD)
6.7.2.3.2. Constipation
6.7.2.3.3. Gastrointestinal Diseases
6.7.2.3.4. Dysbiosis
6.7.2.4. Side Effects of Prebiotics
6.8. The Human Microbiome Project (HMP)
6.8.1. Project Approach
6.8.2. Project Initiatives
6.8.3. Project Achievements
6.9. Regulatory Guidelines for Live Biotherapeutic Products (LBPs)
6.10. Key Challenges Associated with the Development of Microbiome Therapeutics
6.11. Future Perspectives

7.1. Chapter Overview
7.2. Human Microbiome Therapeutics: Overall Market Landscape
7.2.1. Analysis by Stage of Development
7.2.2. Analysis by Type of Molecule
7.2.3. Analysis by Stage of Development and Type of Molecule
7.2.4. Analysis by Type of Biologic
7.2.5. Analysis by Target Indication
7.2.6. Analysis by Therapeutic Area
7.2.7. Analysis by Route of Administration
7.2.8. Analysis by Type of Formulation
7.2.9. Analysis by Dosage Frequency
7.2.10. Analysis by Type of Therapy
7.3. Human Microbiome Therapeutics: Developer Landscape
7.3.1. Analysis by Year of Establishment
7.3.2. Analysis by Company Size
7.3.3. Analysis by Location of Headquarters (Region)
7.3.4. Analysis by Location of Headquarters (Country)
7.3.5. Most Active Players: Analysis by Number of Microbiome Therapeutics

8.1. Chapter Overview
8.2. Overview of Microbiome Diagnostics and Screening / Profiling Tests
8.3. Microbiome Diagnostics and Screening / Profiling Tests: Overall Market Landscape
8.3.1. Analysis by Stage of Development
8.3.2. Analysis by Type of Sample Analyzed
8.3.3. Analysis by Type of Screening Technique
8.3.4. Analysis by Target Indication
8.3.5. Analysis by Therapeutic Area
8.3.6. Analysis by Purpose of Test
8.4. Microbiome Diagnostic and Screening / Profiling Tests: Provider Landscape
8.4.1. Analysis by Year of Establishment
8.4.2. Analysis by Company Size
8.4.3. Analysis by Location of Headquarters (Region)
8.4.4. Analysis by Location of Headquarters (Country)
8.4.5. Most Active Players: Analysis by Number of Microbiome Tests

9.1. Chapter Overview
9.2. Introduction to Fecal Microbiota Therapies (FMT)
9.3. Historical Overview
9.4. Fecal Microbiota Therapies: Procedure and Clinical Relevance
9.4.1. Donor Selection
9.4.2. Administration Procedure
9.4.3. Routes of Administration
9.4.4. Consequences and Adverse Events
9.4.5. Clinical Guidelines Associated with FMT
9.5. Regulatory Guidelines Related to Fecal Microbiota Therapies
9.6. Insurance Coverage for Fecal Microbiota Therapies
9.7. Fecal Microbiota Therapies: Overall Market Landscape
9.7.1. Marketed / Development Pipeline
9.7.1.1. Analysis by Application Area
9.7.1.2. Analysis by Status of Development
9.7.1.3. Analysis by Target Indication
9.7.1.4. Analysis by Therapeutic Area
9.7.1.5. Analysis by Route of Administration
9.7.2. Fecal Microbiota Therapies: Developer Landscape
9.7.2.1. Analysis by Year of Establishment
9.7.2.2. Analysis by Company Size
9.7.2.3. Analysis by Location of Headquarters (Region)
9.7.2.4. Analysis by Location of Headquarters (Country)

10.1. Chapter Overview
10.2. Ferring Pharmaceuticals
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Microbiome-Based Product Portfolio
10.2.3.1. REBYOTA
10.2.3.1.1. Drug Overview
10.2.3.1.2. Current Status of Development
10.2.3.1.3. Clinical Studies
10.2.4. Recent Developments and Future Outlook
10.3. Infant Bacterial Therapeutics
10.4. MaaT Pharma
10.5. Mikrobiomik
10.6. Seres Therapeutics
10.7. OxThera
10.8. Vedanta Biosciences
10.9. Zhiyi Biotech

11.1. Chapter Overview
11.2. Becton, Dickinson and Company
11.2.1. Company Overview
11.2.2. Financial Information
11.2.3. Microbiome Diagnostic Test Portfolio
11.2.4. Recent Developments and Future Outlook
11.3. Biome Diagnostics
11.4. GoodGut
11.5. NutriPATH
11.6. Tiny Health

12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Fecal Microbiota Therapies: Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Analysis of Enrolled Patient Population by Trial Registration Year
12.3.3. Analysis by Trial Status
12.3.4. Analysis of Enrolled Patient Population by Trial Status
12.3.5. Analysis by Trial Registration Year and Trial Status
12.3.6. Analysis by Trial Phase
12.3.7. Analysis of Enrolled Patient Population by Trial Phase
12.3.8. Analysis by Type of Sponsor / Collaborator
12.3.9. Analysis by Study Design
12.3.10. Analysis by Gender
12.3.11. Leading Industry Players: Analysis by Number of Registered Trials
12.3.12. Leading Non-industry Players: Analysis by Number of Registered Trials
12.3.13. Analysis by Trial Status, Trial Phase and Geography
12.3.14. Analysis by Geography
12.3.15. Analysis by Trial Status and Geography
12.3.16. Analysis of Enrolled Patient Population by Trial Status and Geography

13.1. Chapter Overview
13.2. AC Matrix: An Overview
13.2.1. Strong Business Units
13.2.2. Average Business Units
13.2.3. Weak Business Units
13.3. AC Matrix: Analytical Methodology
13.4. AC Matrix: Plotting the Information
13.5. AC Matrix: Analyzing the Data
13.5.1. Strong Business Units
13.5.2. Average Business Units
13.5.3. Weak Business Units
13.6. Concluding Remarks

14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Benchmarking of Start-ups
14.3.1. Analysis by Portfolio Strength
14.3.2. Analysis by Pipeline Maturity
14.3.3. Analysis by Indication Diversity
14.3.4. Analysis by Funding Amount
14.3.5. Analysis by Partnership Activity
14.3.6. Start-up Health Indexing: Analyst's Perspective
14.3.7. Start-up Health Indexing: Leading Companies

15.1. Chapter Overview
15.2. Metabolic Disorders
15.2.1. Diabetes
15.2.1.1. Disease Description
15.2.1.2. Associated Health Risks / Complications
15.2.1.3. Epidemiology
15.2.1.4. Disease Diagnosis
15.2.1.5. Current Treatment Options
15.2.1.5.1. Insulin Therapies
15.2.1.5.2. Non-Insulin Therapies
15.2.1.6. Side Effects of Current Treatment Options
15.2.1.7. Microbiome Therapeutics for Diabetes
15.2.2. Lactose Intolerance
15.2.2.1. Disease Description
15.2.2.2. Epidemiology
15.2.2.3. Current Treatment Options
15.2.2.4. Microbiome Therapeutics for Lactose Intolerance
15.2.3. Nonalcoholic Steatohepatitis (NASH)
15.2.3.1. Disease Description
15.2.3.2. Epidemiology
15.2.3.3. Current Treatment Options
15.2.3.4. Microbiome Therapeutics for NASH
15.2.4. Primary Hyperoxaluria
15.2.4.1. Disease Description
15.2.4.2. Epidemiology
15.2.4.3. Current Treatment Options
15.2.4.4. Microbiome Therapeutics for Primary Hyperoxaluria
15.2.5. Obesity
15.2.5.1. Disease Description
15.2.5.2. Epidemiology
15.2.5.3. Current Treatment Options
15.2.5.4. Side Effects of Current Treatment Options
15.2.5.5. Microbiome Therapeutics for Obesity
15.3. Digestive and Gastrointestinal Disorders
15.3.1. Crohn’s Disease
15.3.1.1. Disease Description
15.3.1.2. Epidemiology
15.3.1.3. Current Treatment Options
15.3.1.4. Side Effects of Current Treatment Options
15.3.1.5. Microbiome Therapeutics for Crohn’s Disease
15.3.2. Irritable Bowel Syndrome (IBS)
15.3.2.1. Disease Description
15.3.2.2. Epidemiology
15.3.2.3. Current Treatment Options
15.3.2.4. Microbiome Therapeutics for IBS
15.3.3. Ulcerative Colitis
15.3.3.1. Disease Description
15.3.3.2. Epidemiology
15.3.3.3. Current Treatment Options
15.3.3.4. Side Effects of Current Treatment Options
15.3.3.5. Microbiome Therapeutics for Ulcerative Colitis
15.4. Oncological Indications
15.4.1. Colorectal Cancer
15.4.1.1. Disease Description
15.4.1.2. Epidemiology
15.4.1.3. Current Treatment Options
15.4.1.4. Side Effects of Current Treatments
15.4.1.5. Microbiome Therapeutics for Colorectal Cancer
15.4.2. Lung Cancer
15.4.2.1. Disease Description
15.4.2.2. Epidemiology
15.4.2.3. Current Treatment Options
15.4.2.4. Side Effects of Current Treatment Options
15.4.2.5. Microbiome Therapeutics for Lung Cancer
15.5. Dermatological Disorders
15.5.1. Acne Vulgaris
15.5.1.1. Disease Description
15.5.1.2. Epidemiology
15.5.1.3. Current Treatment Options
15.5.1.4. Side Effects of Current Treatment Options
15.5.1.5. Microbiome Therapeutics for Acne Vulgaris
15.6. Infectious Diseases
15.6.1. Clostridium Difficile Infections (CDIs)
15.6.1.1. Disease Description
15.6.1.2. Epidemiology
15.6.1.3. Disease Diagnosis
15.6.1.4. Current Treatment Options
15.6.1.5. Side Effects of Current Treatment Options
15.6.1.6. Microbiome Therapeutics for CDI
15.6.2. Bacterial Vaginosis
15.6.2.1. Disease Description
15.6.2.2. Epidemiology
15.6.2.3. Current Treatment Options
15.6.2.4. Side Effects of Current Treatment Options
15.6.2.5. Microbiome Therapeutics for Bacterial Vaginosis

16.1. Chapter Overview
16.2. Partnership Models
16.3. Human Microbiome: List of Partnerships and Collaborations
16.4. Analysis by Year of Partnership
16.5. Analysis by Type of Partnership
16.6. Analysis by Year and Type of Partnership
16.7. Analysis by Target Indication
16.8. Analysis by Therapeutic Area
16.9. Analysis by Type of Partnership and Therapeutic Area
16.10. Analysis by Type of Partner
16.11. Most Active Players: Analysis by Number of Partnerships
16.12. Analysis by Geography
16.12.1. Local and International Deals
16.12.2. Intracontinental and Intercontinental Deals

17.1. Chapter Overview
17.2. Funding Models
17.3. Human Microbiome: List of Funding and Investments
17.3.1. Analysis of Funding Instances by Year of Funding
17.3.2. Analysis of Amount Invested by Year of Funding
17.3.3. Analysis by Type of Funding
17.3.4. Analysis by Year and Type of Funding
17.3.5. Analysis by Amount Invested and Type of Funding
17.3.6. Analysis by Purpose of Funding
17.3.7. Analysis by Target Indication
17.3.8. Analysis by Therapeutic Area
17.3.9. Analysis by Geography
17.3.10. Most Active Players: Analysis by Number of Instances
17.3.11. Most Active Players: Analysis by Amount Invested
17.3.12. Leading Investors: Analysis by Number of Instances
17.3.13. Funding and Investment Summary

18.1. Chapter Overview
18.2. Manufacturing Microbiome Therapeutics
18.2.1. Key Steps Involved
18.2.2. Associated Challenges
18.2.3. Growing Demand for Contract Manufacturing Services
18.2.4. Contract Manufacturing Organizations (CMOs)
18.2.4.1. Introduction to Contract Manufacturing
18.2.5. Microbiome Therapeutics: List of Contract Manufacturing Providers
18.2.5.1. Analysis by Year of Establishment
18.2.5.2. Analysis by Company Size
18.2.5.3. Analysis by Location of Headquarters
18.2.5.4. Analysis by Scale of Operation
18.2.5.5. Analysis by Type of Product Manufactured
18.2.5.6. Analysis by Type of Formulation
18.2.5.7. Analysis by Scale of Operation and Type of Formulation
18.3. Key Considerations for Selecting a CMO / CRO Partner

19.1. Chapter Overview
19.2. Introduction to Big Data
19.3. Internet of Things (IoT)
19.4. Growing Interest in Big Data: Google Trends Analysis
19.5. Key Application Areas
19.6. Big Data in Microbiome Research
19.6.1. Microbiome Data and Personalized Medicine
19.6.2. Microbiome-related Data Management Challenges
19.6.3. National Microbiome Data Center
19.7. Big Data Services for Microbiome Research: List of Companies
19.8. Big Data Services for Microbiome Research: Profiles of Key Players
19.8.1. Human Longevity
19.8.1.1. Company Overview
19.8.1.2. Technology and Service Portfolio
19.8.1.3. Recent Developments and Future Outlook
19.8.2. Resilient Biotics
19.8.2.1. Company Overview
19.8.2.2. Technology and Service Portfolio
19.8.2.3. Recent Developments and Future Outlook
19.8.3. Resphera Biosciences
19.8.3.1. Company Overview
19.8.3.2. Technology and Service Portfolio
19.8.3.3. Recent Developments and Future Outlook

20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Global Human Microbiome Therapeutics Market: Forecasted Estimates (till 2035)
20.4. Human Microbiome Market: Distribution by Type of Product
20.4.1. Therapeutics: Forecasted Estimates (till 2035)
20.4.2. Diagnostics: Forecasted Estimates (till 2035)
20.4.3. Fecal Microbiota Therapies: Forecasted Estimates (till 2035)
20.4.4. Scenario Analysis
20.4.4.1. Conservative Scenario
20.4.4.2. Optimistic Scenario
20.5. Key Market Segmentations

21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Distribution by Type of Biologic
21.3.1. Live Biotherapeutics: Forecasted Estimates (till 2035)
21.3.2. Others: Forecasted Estimates (till 2035)
21.4. Data Triangulation and Validation

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Distribution by Route of Administration
22.3.1. Oral Route: Forecasted Estimates (till 2035)
22.3.2. Rectal Route: Forecasted Estimates (till 2035)
22.4. Data Triangulation and Validation

23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Distribution by Drug Formulation
23.3.1. Capsules: Forecasted Estimates (till 2035)
23.3.2. Suspensions: Forecasted Estimates (till 2035)
23.3.3. Enemas: Forecasted Estimates (till 2035)
23.3.4. Powders: Forecasted Estimates (till 2035)
23.4. Data Triangulation and Validation

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Distribution by Target Indication
24.3.1. Clostridium Difficile Infection
24.3.2. Necrotizing Enterocolitis
24.3.3. Irritable Bowel Syndrome
24.3.4. Acute Graft Versus Host Disease
24.4. Data Triangulation and Validation

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Distribution by Therapeutic Area
25.3.1. Infectious Diseases
25.3.2. Gastrointestinal Disorders
25.3.3. Rare Disorders
25.4. Data Triangulation and Validation

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Distribution by Geographical Regions
26.3.1. North America
26.3.2. Europe
26.3.3. Asia-Pacific
26.3.4. Latin America
26.3.5. Middle East and North Africa
26.4. Market Dynamics Assessment
26.4.1. Penetration Growth (P-G) Matrix
26.4.2. Market Movement Analysis
26.5. Data Triangulation and Validation

27.1. Chapter Overview
27.2. Assumptions and Methodology
27.3. Global Human Microbiome Diagnostics Market: Forecasted Estimates (till 2035)
27.3.1. Scenario Analysis
27.4. Key Market Segmentations

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Market Distribution by Target Indication
28.3.1. Diabetes Mellitus: Forecasted Estimates (till 2035)
28.3.2. Irritable Bowel Syndrome: Forecasted Estimates (till 2035)
28.3.3. Irritable Bowel Disease: Forecasted Estimates (till 2035)
28.3.4. Colorectal Cancer: Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Market Distribution by Therapeutic Area
29.3.1. Gastrointestinal Disorders: Forecasted Estimates (till 2035)
29.3.2. Metabolic Disorders: Forecasted Estimates (till 2035)
29.3.3. Oncological Disorders: Forecasted Estimates (till 2035)
29.4. Data Triangulation and Validation

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Market Distribution by Geographical Regions
30.3.1. North America: Forecasted Estimates (till 2035)
30.3.2. Europe: Forecasted Estimates (till 2035)
30.3.3. Asia-Pacific: Forecasted Estimates (till 2035)
30.3.4. Latin America: Forecasted Estimates (till 2035)
30.3.5. Middle East and North Africa: Forecasted Estimates (till 2035)
30.4. Data Triangulation and Validation
30.5. Market Dynamics Assessment
30.5.1. Penetration Growth (P-G) Matrix
30.5.2. Market Movement Analysis
30.6. Data Triangulation and Validation

31.1. Chapter Overview
31.2. Assumptions and Methodology
31.3. Global Market: Forecasted Estimates (till 2035)
31.3.1. Scenario Analysis
31.3.1.1. Conservative Scenario
31.3.1.2. Optimistic Scenario
31.4. Key Market Segmentations

32.1. Chapter Overview
32.2. Key Assumptions and Methodology
32.3. Distribution by Geographic Regions
32.3.1. North America
32.3.2. Europe
32.3.3. Asia-Pacific
32.3.4. Latin America
32.3.5. Middle East and North Africa
32.4. Data Triangulation and Validation
32.5. Market Dynamics Assessment
32.5.1. Penetration Growth (P-G) Matrix
32.5.2. Market Movement Analysis
32.6. Data Triangulation and Validation

33.1. Market Distribution by Type of Biologic
33.2. Market Distribution by Route of Administration
33.3. Market Distribution by Drug Formulation
33.4. Market Distribution by Target Indication
33.5. Market Distribution by Target Therapeutic Area

34.1. Market Distribution by Type of Biologic
34.2. Market Distribution by Route of Administration
34.3. Market Distribution by Drug Formulation
34.4. Market Distribution by Target Indication
34.5. Market Distribution by Target Therapeutic Area

35.1. Market Distribution by Type of Biologic
35.2. Market Distribution by Route of Administration
35.3. Market Distribution by Drug Formulation
35.4. Market Distribution by Target Indication
35.5. Market Distribution by Target Therapeutic Area

36.1. Market Distribution by Type of Biologic
36.2. Market Distribution by Route of Administration
36.3. Market Distribution by Drug Formulation
36.4. Market Distribution by Target Indication
36.5. Market Distribution by Target Therapeutic Area

37.1. Market Distribution by Type of Biologic
37.2. Market Distribution by Route of Administration
37.3. Market Distribution by Drug Formulation
37.4. Market Distribution by Target Indication
37.5. Market Distribution by Target Therapeutic Area

38.1. Distribution by Target Indication
38.2. Distribution by Target Therapeutic Area

39.1. Distribution by Target Indication
39.2. Distribution by Target Therapeutic Area

40.1. Distribution by Target Indication
40.2. Distribution by Target Therapeutic Area

41.1. Distribution by Target Indication
41.2. Distribution by Target Therapeutic Area

42.1. Distribution by Target Indication
42.2. Distribution by Target Therapeutic Area

44.1. Chapter Overview
44.2. Company A (Mid-sized Company, UK)
44.2.1. Company Snapshot
44.2.2. Interview Transcript: Former Senior Manager, Corporate Development
44.3. Company B (Small Company, US)
44.3.1. Company Snapshot
44.3.2. Interview Transcript: Co-founder and Chairman
44.4. Company C (Small Company, US)
44.4.1. Company Snapshot
44.4.2. Interview Transcript: Chief Executive Officer
44.5. Company D (Large Company, US)
44.5.1. Company Snapshot
44.5.2. Interview Transcript: Senior Scientist
44.6. Company E (Small Company, Taiwan)
44.6.1. Company Snapshot
44.6.2. Interview Transcript: President
44.7. Company F (Small Company, US)
44.7.1. Company Snapshot
44.7.2. Interview Transcript: Vice President, Business Development
44.8. Company G (Mid-sized Company, Israel)
44.8.1. Company Snapshot
44.8.2. Interview Transcript: Chief Business Officer
44.9. Company H (Small Company, US)
44.9.1. Company Snapshot
44.9.2. Interview Transcript: Former Vice President, Sales and Business Development
44.10. Company I (Small Company, Belgium)
44.10.1. Company Snapshot
44.10.2. Interview Transcript: Co-founder and Chief Executive Officer
44.11. Company J (Small Company, US)
44.11.1. Company Snapshot
44.11.2. Interview Transcript: Co-founder and Chief Executive Officer
44.12. Company K (Small Company, US)
44.12.1. Company Snapshot
44.12.2. Interview Transcript: Co-founder and Chief Executive Officer
44.13. Company L (Mid-sized Company, US)
44.13.1. Company Snapshot
44.13.2. Interview Transcript: Ex-Co-founder and Vice President of Innovation
44.14. Company M (Small Company, US)
44.14.1. Company Snapshot
44.14.2. Interview Transcript: Vice President & Chief Operating Officer
44.15. Company N (Mid-sized Company, US)
44.15.1. Company Snapshot
44.15.2. Interview Transcript: Former Vice President, Operations
44.16. Company O (Small Company, US)
44.16.1. Company Snapshot
44.16.2. Interview Transcript: Former President and Chief Executive Officer
44.17. Company P (Small Company, US)
44.17.1. Company Snapshot
44.17.2. Interview Transcript: Former Chief Scientific Officer and Vice President, Research
44.18. Company Q (Small Company, France)
44.18.1. Company Snapshot
44.18.2. Interview Transcript: Former Chief Strategy Officer

Table 6.1 Types of Microbiota in the Gastrointestinal Tract
Table 6.2 Common Instances of Misuse of Antibiotics
Table 6.3 Impact of Antibiotics on Intestinal Microflora
Table 6.4 List of Microorganisms Classified as Class I Carcinogens by the IARC
Table 6.5 Relationship Between Microbiome and Disease Progression
Table 6.6 Impact of Drug-Microbiome Interactions
Table 6.7 List of Foods Containing Prebiotics
Table 7.1 Microbiome Therapeutics: Information on Type of Molecule and Route of Administration
Table 7.2 Microbiome Therapeutics: Additional Information
Table 7.3 Microbiome Therapeutics: List of Drug Developers
Table 8.1 Microbiome Diagnostics and Screening / Profiling Tests: Marketed and Development Pipeline
Table 8.2 Microbiome Diagnostics and Screening / Profiling Tests: List of Developers
Table 9.1 Comparison between Various Routes of Administration of FMT
Table 9.2 FMT: Summary of Clinical Guidelines
Table 9.3 FMT: Summary of Insurance Coverage Payer
Table 9.4 FMT: Marketed and Development Pipeline
Table 9.5 FMT: List of Developers
Table 10.1 Ferring Pharmaceuticals: Company Overview
Table 10.2 Ferring Pharmaceuticals: Microbiome-Based Product Portfolio
Table 10.3 REBYOTA: Current Status of Development
Table 10.4 REBYOTA: Clinical Studies
Table 10.5 Ferring Pharmaceuticals: Recent Developments and Future Outlook
Table 10.6 Infant Bacterial Therapeutics: Company Overview
Table 10.7 Infant Bacterial Therapeutics: Microbiome-Based Product Portfolio
Table 10.8 IBP-9414: Current Status of Development
Table 10.9 IBP-9414: Clinical Studies
Table 10.10 Infant Bacterial Therapeutics: Recent Developments and Future Outlook
Table 10.11 MaaT Pharma: Company Overview
Table 10.12 MaaT Pharma: Microbiome-Based Product Portfolio
Table 10.13 MaaT013: Current Status of Development
Table 10.14 MaaT013: Clinical Studies
Table 10.15 MaaT Pharma: Recent Developments and Future Outlook
Table 10.16 Mikrobiomik: Company Overview
Table 10.17 Mikrobiomik: Microbiome-Based Product Portfolio
Table 10.18 MBK-01: Current Status of Development
Table 10.19 MBK-01: Clinical Studies
Table 10.20 Mikrobiomik: Recent Developments and Future Outlook
Table 10.21 Seres Therapeutics: Company Overview
Table 10.22 Seres Therapeutics: Microbiome-Based Product Portfolio
Table 10.23 SER-109 / VOWST: Current Status of Development
Table 10.24 SER-109 / VOWST: Clinical Studies
Table 10.25 Seres Therapeutics: Recent Developments and Future Outlook
Table 10.26 OxThera: Company Overview
Table 10.27 OxThera: Microbiome-Based Product Portfolio
Table 10.28 Oxabact: Current Status of Development
Table 10.29 Oxabact: Clinical Studies
Table 10.30 OxThera: Recent Developments and Future Outlook
Table 10.31 Vedanta Biosciences: Company Overview
Table 10.32 Vedanta Biosciences: Microbiome-Based Product Portfolio
Table 10.33 VE303: Current Status of Development
Table 10.34 VE303: Clinical Studies
Table 10.35 Vedanta Biosciences: Recent Developments and Future Outlook
Table 10.36 Zhiyi Biotech: Company Overview
Table 10.37 Zhiyi Biotech: Microbiome-Based Product Portfolio
Table 10.38 SK08: Current Status of Development
Table 10.39 SK08: Clinical Studies
Table 10.40 Zhiyi Biotech: Recent Developments and Future Outlook
Table 11.1 Becton, Dickinson and Company: Company Overview
Table 11.2 Becton, Dickinson and Company: Microbiome Test Portfolio
Table 11.3 Becton, Dickinson and Company: Recent Developments and Future Outlook
Table 11.4 Biome Diagnostics: Company Overview
Table 11.5 Biome Diagnostics: Microbiome Test Portfolio
Table 11.6 Biome Diagnostics: Recent Developments and Future Outlook
Table 11.7 GoodGut: Company Overview
Table 11.8 GoodGut: Microbiome Test Portfolio
Table 11.9 GoodGut: Recent Developments and Future Outlook
Table 11.10 NutriPATH: Company Overview
Table 11.11 NutriPATH: Microbiome Test Portfolio
Table 11.12 NutriPATH: Recent Developments and Future Outlook
Table 11.13 Tiny Health: Company Overview
Table 11.14 Tiny Health: Microbiome Test Portfolio
Table 11.15 Tiny Health: Recent Developments and Future Outlook
Table 12.1 Fecal Microbiota Transplant: List of Registered Clinical Trials
Table 15.1 Diabetes: Current Treatment Options
Table 15.2 Diabetes: Side Effects of Current Treatment Options
Table 15.3 Microbiome Therapeutics Candidates for Diabetes
Table 15.4 Microbiome Therapeutics Candidates for Lactose Intolerance
Table 15.5 Microbiome Therapeutics Candidates for NASH
Table 15.6 Microbiome Therapeutics Candidates for Primary Hyperoxaluria
Table 15.7 Obesity: Side Effects of Current Treatment Options
Table 15.8 Microbiome Therapeutic Candidates for Obesity
Table 15.9 Crohn’s Disease: Current Treatment Options
Table 15.10 Crohn’s Disease: Side Effects of Current Treatment Options
Table 15.11 Microbiome Therapeutics Candidates for Crohn’s Disease
Table 15.12 IBS: Current Treatment Options
Table 15.13 Microbiome Therapeutics Candidates for IBS
Table 15.14 Ulcerative Colitis: Current Treatment Options
Table 15.15 Ulcerative Colitis: Side Effects of Current Treatment Options
Table 15.16 Microbiome Therapeutics Candidates for Ulcerative Colitis
Table 15.17 Colorectal Cancer: Side Effects of Current Treatment Options
Table 15.18 Microbiome Therapeutics Pipeline for Colorectal Cancer
Table 15.19 Lung Cancer: Current Treatment Options
Table 15.20 Lung Cancer: Side Effects of Current Treatment Options
Table 15.21 Microbiome Therapeutics Candidates for Lung Cancer
Table 15.22 Acne Vulgaris: Current Treatment Options
Table 15.23 Acne Vulgaris: Side Effects of Current Treatment Options
Table 15.24 Microbiome Therapeutics Candidates for Acne Vulgaris
Table 15.25 CDI: Diagnostic Testing
Table 15.26 CDI: Severity Scoring System and Treatment Options
Table 15.27 CDI: Side Effects of Current Treatment Options
Table 15.28 Microbiome Therapeutics Candidates for CDI
Table 15.29 Bacterial Vaginosis: Current Treatment Options
Table 15.30 Bacterial Vaginosis: Side Effects of Current Treatment Options
Table 15.31 Microbiome Therapeutics Candidates for Bacterial Vaginosis
Table 16.1 Human Microbiome: List of Partnerships and Collaborations, Since 2022
Table 17.1 Human Microbiome: Funding and Investments, Information on Funding Type, Year, Amount and Investor, Since 2022
Table 17.2 Human Microbiome: Funding and Investments, Information on Type of Product, Target Indication and Focus Area, Since 2022
Table 17.3 Human Microbiome: Funding and Investments, Information on Type of Investor and Location of Headquarters, Since 2022
Table 18.1 Microbiome Contract Manufacturers: Information on Year of Establishment, Headquarters, Company Size, Accreditation Received and Scale of Operation
Table 18.2 Microbiome Contract Manufacturers: Information on Type of Product Manufactured
Table 18.3 Microbiome Contract Manufacturers: Information on Type of Formulation
Table 18.4 Comparison of Key Factors for the Selection of Contract Service Providers: Harvey Ball Analysis
Table 19.1 List of Companies Using Big Data for Microbiome Research
Table 19.2 Human Longevity: Partnerships and Collaborations
Table 19.3 Human Longevity: Venture Capital Funding
Table 19.4 Resilient Biotics: Venture Capital Funding
Table 20.1 List of Companies Engaged in the Development of Microbiome Products for Other Applications
Table 20.2 Pipeline of Microbiome Based Consumer Products, Medical Foods and Supplements
Table 44.1 Company A: Company Snapshot
Table 44.2 Company B: Company Snapshot
Table 44.3 Company C: Company Snapshot
Table 44.4 Company D: Company Snapshot
Table 44.5 Company E: Company Snapshot
Table 44.6 Company F: Company Snapshot
Table 44.7 Company G: Company Snapshot
Table 44.8 Company H: Company Snapshot
Table 44.9 Company I: Company Snapshot
Table 44.10 Company J: Company Snapshot
Table 44.11 Company K: Company Snapshot
Table 44.12 Company L: Company Snapshot
Table 44.13 Company M: Company Snapshot
Table 44.14 Company N: Company Snapshot
Table 44.15 Company O: Company Snapshot
Table 44.16 Company P: Company Snapshot
Table 44.17 Company Q: Company Snapshot
Table 45.1 Microbiome Therapeutics: Distribution by Stage of Development
Table 45.2 Microbiome Therapeutics: Distribution by Type of Molecule
Table 45.3 Microbiome Therapeutics: Distribution by Stage of Development and Type of Molecule
Table 45.4 Microbiome Therapeutics: Distribution by Type of Biologic
Table 45.5 Microbiome Therapeutics: Distribution by Target Indication
Table 45.6 Microbiome Therapeutics: Distribution by Therapeutic Area
Table 45.7 Microbiome Therapeutics: Distribution by Route of Administration
Table 45.8 Microbiome Therapeutics: Distribution by Type of Formulation
Table 45.9 Microbiome Therapeutics: Distribution by Dose Frequency
Table 45.10 Microbiome Therapeutics: Distribution by Type of Therapy
Table 45.11 Microbiome Therapeutic Developers: Distribution by Year of Establishment
Table 45.12 Microbiome Therapeutic Developers: Distribution by Company Size
Table 45.13 Microbiome Therapeutic Developers: Distribution by Location of Headquarters (Region)
Table 45.14 Microbiome Therapeutic Developers: Distribution by Location of Headquarters (Country)
Table 45.15 Microbiome Therapeutic Developers: Distribution by Most Active Players
Table 45.16 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development
Table 45.17 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Sample Analyzed
Table 45.18 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Screening Technique
Table 45.19 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Target Indication
Table 45.20 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Therapeutic Area
Table 45.21 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Purpose of Test
Table 45.22 Microbiome Diagnostic and Screening / Profiling Test Providers: Distribution by Year of Establishment
Table 45.23 Microbiome Diagnostic and Screening / Profiling Test Providers: Distribution by Company Size
Table 45.24 Microbiome Diagnostic and Screening / Profiling Test Providers: Distribution by Location of Headquarters (Region)
Table 45.25 Microbiome Diagnostic and Screening / Profiling Test Providers: Distribution by Location of Headquarters (Country)
Table 45.26 Microbiome Diagnostic and Screening / Profiling Test Providers: Distribution by Most Active Players
Table 45.27 Fecal Microbiota Therapies: Distribution by Application Area
Table 45.28 Fecal Microbiota Therapies: Distribution by Status of Development
Table 45.29 Fecal Microbiota Therapies: Distribution by Target Indication
Table 45.30 Fecal Microbiota Therapies: Distribution by Therapeutic Area
Table 45.31 Fecal Microbiota Therapies: Distribution by Route of Administration
Table 45.32 Fecal Microbiota Therapy Developers: Distribution by Year of Establishment
Table 45.33 Fecal Microbiota Therapy Developers: Distribution by Company Size
Table 45.34 Fecal Microbiota Therapy Developers: Distribution by Location of Headquarters (Region)
Table 45.35 Fecal Microbiota Therapy Developers: Distribution by Location of
Headquarters (Country)
Table 45.36 Ferring Pharmaceuticals: Financial Information, Since 2021 (USD Million)
Table 45.37 Infant Bacterial Therapeutics: Financial Information, Since 2021 (USD Million)
Table 45.38 MaaT Pharma: Financial Information, Since 2021 (USD Million)
Table 45.39 Microbiomik: Financial Information, Since 2021 (USD Million)
Table 45.40 Seres Therapeutics: Financial Information, Since 2021 (USD Million)
Table 45.41 OxThera: Financial Information, Since 2021 (USD Million)
Table 45.42 Vedanta Biosciences: Financial Information, Since 2021 (USD Million)
Table 45.43 Zhiyi Biotech: Financial Information, Since 2021 (USD Million)
Table 45.44 Becton, Dickinson and Company: Financial Information, Since 2021 (USD Million)
Table 45.45 Biome Diagnostics: Financial Information, Since 2021 (USD Million)
Table 45.46 GoodGut: Financial Information, Since 2021 (USD Million)
Table 45.47 NutriPATH: Financial Information, Since 2021 (USD Million)
Table 45.48 Tiny Health: Financial Information, Since 2021 (USD Million)
Table 45.49 Clinical Trial Analysis: Scope and Methodology
Table 45.50 Clinical Trial Analysis: Distribution by Trial Status
Table 45.51 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Since 2021
Table 45.52 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Since 2021
Table 45.53 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Recruitment Status
Table 45.54 Clinical Trial Analysis: Distribution by Trial Phase and Number of Patients Enrolled
Table 45.55 Clinical Trial Analysis: Distribution by Study Design
Table 45.56 Leading Industry Players: Distribution by Number of Registered Trials
Table 45.57 Leading Non-industry Players: Distribution by Number of Registered Trials
Table 45.58 Clinical Trial Analysis: Analysis by Trial Location
Table 45.59 Clinical Trial Analysis: Analysis by Trial Status and Geography
Table 45.60 Start-up Health Indexing: Portfolio Strength
Table 45.61 Start-up Health Indexing: Pipeline Maturity
Table 45.62 Start-up Health Indexing: Indication Diversity
Table 45.63 Start-up Health Indexing: Funding Amount
Table 45.64 Start-up Health Indexing: Partnership Activity
Table 45.65 Obese Population: Distribution by Key Regions
Table 45.66 Partnerships and Collaborations: Distribution of Cumulative Year-wise Trend, Since 2022
Table 45.67 Partnerships and Collaborations: Distribution of Type of Partnership
Table 45.68 Partnerships and Collaborations: Distribution of Year and Type of Partnership, Since 2022
Table 45.69 Partnerships and Collaborations: Distribution of Target Indication
Table 45.70 Partnerships and Collaborations: Distribution of Therapeutic Area
Table 45.71 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Table 45.72 Partnerships and Collaborations: Distribution by Type of Partner
Table 45.73 Most Active Players: Distribution by Number of Partnerships
Table 45.74 Partnerships and Collaborations: Local and International Deals
Table 45.75 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 45.76 Funding and Investments: Cumulative Year-wise Distribution of Funding Instances, Since 2022
Table 45.77 Funding and Investments: Cumulative Year-wise Distribution of Amount Invested (USD Million), Since 2022
Table 45.78 Funding and Investments: Distribution by Year of Funding and Amount Invested (USD Million), Since 2022
Table 45.79 Funding and Investments: Distribution by Type of Funding
Table 45.80 Funding and Investments: Distribution by Year of Funding and Type of Funding, 2022-2025 (till August)
Table 45.81 Funding and Investments: Distribution by Type of Funding and Amount Invested (USD Million)
Table 45.82 Funding and Investments: Distribution by Purpose of Funding
Table 45.83 Funding and Investments: Distribution by Target Indication
Table 45.84 Funding and Investments: Distribution by Therapeutic Area
Table 45.85 Funding and Investments: Distribution by Geography
Table 45.86 Most Active Players: Distribution by Number of Instances
Table 45.87 Most Active Players: Distribution by Amount Invested (USD Million)
Table 45.88 Key Investors: Distribution by Number of Funding Instances
Table 45.89 Funding and Investment Summary, Since 2022
Table 45.90 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
Table 45.91 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
Table 45.92 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
Table 45.93 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation
Table 45.94 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
Table 45.95 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
Table 45.96 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
Table 45.97 Global Human Microbiome Therapeutics Market, Forecasted Estimates (till 2035) (USD Million)
Table 45.98 Global Human Microbiome Therapeutics Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Table 45.99 Human Microbiome Therapeutics Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Table 45.100 Human Microbiome Market: Distribution by Type of Product
Table 45.101 Human Microbiome Market for Therapeutics: Forecasted Estimates (till 2035) (USD Million)
Table 45.102 Human Microbiome Market for Diagnostics: Forecasted Estimates (till 2035) (USD Million)
Table 45.103 Human Microbiome Market for Fecal Microbiota Therapies: Forecasted Estimates (till 2035) (USD Million)
Table 45.104 Human Microbiome Therapeutics Market: Distribution by Type of Biologic
Table 45.105 Human Microbiome Therapeutics Market for Live Biotherapeutics: Forecasted Estimates (till 2035) (USD Million)
Table 45.106 Human Microbiome Therapeutics Market for Others: Forecasted Estimates (till 2035) (USD Million)
Table 45.107 Human Microbiome Therapeutics Market: Distribution by Route of Administration
Table 45.108 Human Microbiome Therapeutics Market for Oral Route: Forecasted Estimates (till 2035) (USD Million)
Table 45.109 Human Microbiome Therapeutics Market for Rectal Route: Forecasted Estimates (till 2035) (USD Million)
Table 45.110 Human Microbiome Therapeutics Market: Distribution by Drug Formulation
Table 45.111 Human Microbiome Therapeutics Market for Capsules: Forecasted Estimates (till 2035) (USD Million)
Table 45.112 Human Microbiome Therapeutics Market for Suspensions: Forecasted Estimates (till 2035) (USD Million)
Table 45.113 Human Microbiome Therapeutics Market for Enemas: Forecasted Estimates (till 2035) (USD Million)
Table 45.114 Human Microbiome Therapeutics Market for Powders: Forecasted Estimates (till 2035) (USD Million)
Table 45.115 Human Microbiome Therapeutics Market: Distribution by Target Indication
Table 45.116 Human Microbiome Therapeutics Market for Clostridium Difficile Infection: Forecasted Estimates (till 2035) (USD Million)
Table 45.117 Human Microbiome Therapeutics Market for Necrotizing Enterocolitis: Forecasted Estimates (till 2035) (USD Million)
Table 45.118 Human Microbiome Therapeutics Market for Irritable Bowel Syndrome: Forecasted Estimates (till 2035) (USD Million)
Table 45.119 Human Microbiome Therapeutics Market for Acute Graft Versus Host Disease: Forecasted Estimates (till 2035) (USD Million)
Table 45.120 Human Microbiome Therapeutics Market: Distribution by Target Therapeutic Area
Table 45.121 Human Microbiome Therapeutics Market for Infectious Diseases: Forecasted Estimates (till 2035) (USD Million)
Table 45.122 Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Forecasted Estimates (till 2035) (USD Million)
Table 45.123 Human Microbiome Therapeutics Market for Rare Disorders: Forecasted Estimates (till 2035) (USD Million)
Table 45.124 Human Microbiome Therapeutics Market: Distribution by Geographical Regions
Table 45.125 Human Microbiome Therapeutics Market in North America: Forecasted Estimates (till 2035) (USD Million)
Table 45.126 Human Microbiome Therapeutics Market in the US: Forecasted Estimates (till 2035) (USD Million)
Table 45.127 Human Microbiome Therapeutics Market in Canada: Forecasted Estimates (till 2035) (USD Million)
Table 45.128 Human Microbiome Therapeutics Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Table 45.129 Human Microbiome Therapeutics Market in Germany: Forecasted Estimates (till 2035) (USD Million)
Table 45.130 Human Microbiome Therapeutics Market in the UK: Forecasted Estimates (till 2035) (USD Million)
Table 45.131 Human Microbiome Therapeutics Market in Spain: Forecasted Estimates (till 2035) (USD Million)
Table 45.132 Human Microbiome Therapeutics Market in France: Forecasted Estimates (till 2035) (USD Million)
Table 45.133 Human Microbiome Therapeutics Market in Italy: Forecasted Estimates (till 2035) (USD Million)
Table 45.134 Human Microbiome Therapeutics Market in Rest of Europe: Forecasted Estimates (till 2035) (USD Million)
Table 45.135 Human Microbiome Therapeutics Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Million)
Table 45.136 Human Microbiome Therapeutics Market in China: Forecasted Estimates (till 2035) (USD Million)
Table 45.137 Human Microbiome Therapeutics Market in Australia: Forecasted Estimates (till 2035) (USD Million)
Table 45.138 Human Microbiome Therapeutics Market in Latin America: Forecasted Estimates (till 2035) (USD Million)
Table 45.139 Human Microbiome Therapeutics Market in Brazil: Forecasted Estimates (till 2035) (USD Million)
Table 45.140 Human Microbiome Therapeutics Market in Middle East and North Africa: Forecasted Estimates (till 2035) (USD Million)
Table 45.141 Global Human Microbiome Diagnostics Market, Forecasted Estimates (till 2035) (USD Million)
Table 45.142 Global Human Microbiome Diagnostics Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Table 45.143 Human Microbiome Diagnostics Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Table 45.144 Human Microbiome Diagnostics Market: Distribution by Target Indication
Table 45.145 Human Microbiome Diagnostics Market for Diabetes Mellitus: Forecasted Estimates (till 2035) (USD Million)
Table 45.146 Human Microbiome Diagnostics Market for Irritable Bowel Syndrome: Forecasted Estimates (till 2035) (USD Million)
Table 45.147 Human Microbiome Diagnostics Market for Irritable Bowel Disease: Forecasted Estimates (till 2035) (USD Million)
Table 45.148 Human Microbiome Diagnostics Market for Colorectal Cancer: Forecasted Estimates (till 2035) (USD Million)
Table 45.149 Human Microbiome Diagnostics Market: Distribution by Target Therapeutic Area
Table 45.150 Human Microbiome Diagnostics Market for Gastrointestinal Disorders: Forecasted Estimates (till 2035) (USD Million)
Table 45.151 Human Microbiome Diagnostics Market for Metabolic Disorders: Forecasted Estimates (till 2035) (USD Million)
Table 45.152 Human Microbiome Diagnostics Market for Oncological Disorders: Forecasted Estimates (till 2035) (USD Million)
Table 45.153 Human Microbiome Diagnostics Market: Distribution by Geographical Regions
Table 45.154 Human Microbiome Diagnostics Market in North America: Forecasted Estimates (till 2035) (USD Million)
Table 45.155 Human Microbiome Diagnostics Market in the US: Forecasted Estimates (till 2035) (USD Million)
Table 45.156 Human Microbiome Diagnostics Market in Canada: Forecasted Estimates (till 2035) (USD Million)
Table 45.157 Human Microbiome Diagnostics Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Table 45.158 Human Microbiome Diagnostics Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Million)
Table 45.159 Human Microbiome Diagnostics Market in China: Forecasted Estimates (till 2035) (USD Million)
Table 45.160 Human Microbiome Diagnostics Market in India: Forecasted Estimates (till 2035) (USD Million)
Table 45.161 Human Microbiome Diagnostics Market in Japan: Forecasted Estimates (till 2035) (USD Million)
Table 45.162 Human Microbiome Diagnostics Market in Latin America: Forecasted Estimates (till 2035) (USD Million)
Table 45.163 Human Microbiome Diagnostics Market in Brazil: Forecasted Estimates (till 2035) (USD Million)
Table 45.164 Human Microbiome Diagnostics Market in Middle East and North Africa: Forecasted Estimates (till 2035) (USD Million)
Table 45.165 Human Microbiome Diagnostics Market in Saudi Arabia: Forecasted Estimates (till 2035) (USD Million)
Table 45.166 Global Human Microbiome Fecal Microbiota Therapies Market, Forecasted Estimates (till 2035) (USD Million)
Table 45.167 Global Human Microbiome Fecal Microbiota Therapies Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Table 45.168 Human Microbiome Fecal Microbiota Therapies Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Table 45.169 Human Microbiome Fecal Microbiota Therapies Market: Distribution by Geographical Regions
Table 45.170 Human Microbiome Fecal Microbiota Therapies Market in North America: Forecasted Estimates (till 2035) (USD Million)
Table 45.171 Human Microbiome Fecal Microbiota Therapies Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Table 45.172 Human Microbiome Fecal Microbiota Therapies Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Million)
Table 45.173 Human Microbiome Fecal Microbiota Therapies Market in Latin America: Forecasted Estimates (till 2035) (USD Million)
Table 45.174 Human Microbiome Fecal Microbiota Therapies Market in Middle East and
North Africa: Forecasted Estimates (till 2035) (USD Million)

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Benefits of the Human Microbiota
Figure 6.2 Factors Affecting Gut Microbiota
Figure 6.3 Factors Affecting Gut Microbiota in Infants
Figure 6.4 Impact of Diet on Gut Microbiota
Figure 6.5 Types of Microbiome-Based Therapeutics
Figure 6.6 Approaches to Design Microbiome Therapeutics
Figure 6.7 Health Benefits of Probiotics
Figure 6.8 Mechanism of Action of Probiotics
Figure 6.9 Beneficial Bacterial Strains for Probiotics
Figure 6.10 Key Achievements of the Human Microbiome Project (HMP)
Figure 6.11 Challenges Associated with the Development of Microbiome Therapeutics
Figure 7.1 Microbiome Therapeutics: Distribution by Stage of Development
Figure 7.2 Microbiome Therapeutics: Distribution by Type of Molecule
Figure 7.3 Microbiome Therapeutics: Distribution by Stage of Development and Type of Molecule
Figure 7.4 Microbiome Therapeutics: Distribution by Type of Biologic
Figure 7.5 Microbiome Therapeutics: Distribution by Target Indication
Figure 7.6 Microbiome Therapeutics: Distribution by Therapeutic Area
Figure 7.7 Microbiome Therapeutics: Distribution by Route of Administration
Figure 7.8 Microbiome Therapeutics: Distribution by Type of Formulation
Figure 7.9 Microbiome Therapeutics: Distribution by Dose Frequency
Figure 7.10 Microbiome Therapeutics: Distribution by Type of Therapy
Figure 7.11 Microbiome Therapeutic Developers: Distribution by Year of Establishment
Figure 7.12 Microbiome Therapeutic Developers: Distribution by Company Size
Figure 7.13 Microbiome Therapeutic Developers: Distribution by Location of Headquarters (Region)
Figure 7.14 Microbiome Therapeutic Developers: Distribution by Location of Headquarters (Country)
Figure 7.15 Most Active Players: Distribution by Number of Microbiome Therapies
Figure 8.1 Key Steps in 16S rRNA Gene Sequence Analysis
Figure 8.2 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Stage of Development
Figure 8.3 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Sample Analyzed
Figure 8.4 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Type of Screening Technique
Figure 8.5 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Target Indication
Figure 8.6 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Therapeutic Area
Figure 8.7 Microbiome Diagnostics and Screening / Profiling Tests: Distribution by Purpose of Test
Figure 8.8 Microbiome Diagnostic and Screening / Profiling Test Providers: Distribution by Year of Establishment
Figure 8.9 Microbiome Diagnostic and Screening / Profiling Test Providers: Distribution by Company Size
Figure 8.10 Microbiome Diagnostic and Screening / Profiling Test Providers: Distribution by Location of Headquarters (Region)
Figure 8.11 Microbiome Diagnostic and Screening / Profiling Test Providers: Distribution by Location of Headquarters (Country)
Figure 8.12 Most Active Players: Distribution by Number of Microbiome Tests
Figure 9.1 Working Mechanism of a Microflora Refinement System
Figure 9.2 Fecal Microbiota Therapies: Distribution by Application Area
Figure 9.3 Fecal Microbiota Therapies: Distribution by Status of Development
Figure 9.4 Fecal Microbiota Therapies: Distribution by Target Indication
Figure 9.5 Fecal Microbiota Therapies: Distribution by Therapeutic Area
Figure 9.6 Fecal Microbiota Therapies: Distribution by Route of Administration
Figure 9.7 Fecal Microbiota Therapy Developers: Distribution by Year of Establishment
Figure 9.8 Fecal Microbiota Therapy Developers: Distribution by Company Size
Figure 9.9 Fecal Microbiota Therapy Developers: Distribution by Location of Headquarters (Region)
Figure 9.10 Fecal Microbiota Therapy Developers: Distribution by Location of Headquarters (Country)
Figure 10.1 Ferring Pharmaceuticals: Financial Information, Since 2021 (USD Million)
Figure 10.2 Infant Bacterial Therapeutics: Financial Information, Since 2021 (USD Million)
Figure 10.3 MaaT Pharma: Financial Information, Since 2021 (USD Million)
Figure 10.4 Microbiomik: Financial Information, Since 2021 (USD Million)
Figure 10.5 Seres Therapeutics: Financial Information, Since 2021 (USD Million)
Figure 10.6 OxThera: Financial Information, Since 2021 (USD Million)
Figure 10.7 Vedanta Biosciences: Financial Information, Since 2021 (USD Million)
Figure 10.8 Zhiyi Biotech: Financial Information, Since 2021 (USD Million)
Figure 11.1 Becton, Dickinson and Company: Financial Information, Since 2021 (USD Million)
Figure 11.2 Biome Diagnostics: Financial Information, Since 2021 (USD Million)
Figure 11.3 GoodGut: Financial Information, Since 2021 (USD Million)
Figure 11.4 NutriPATH: Financial Information, Since 2021 (USD Million)
Figure 11.5 Tiny Health: Financial Information, Since 2021 (USD Million)
Figure 12.1 Distribution by Trial Registration Year
Figure 12.2 Distribution of Enrolled Patient Population by Trial Registration Year
Figure 12.3 Distribution by Trial Status
Figure 12.4 Distribution of Enrolled Patient Population by Trial Status
Figure 12.5 Distribution by Trial Registration Year and Trial Status
Figure 12.6 Distribution by Trial Phase
Figure 12.7 Distribution of Enrolled Patient Population by Trial Phase
Figure 12.8 Distribution by Type of Sponsor / Collaborator
Figure 12.9 Distribution by Study Design
Figure 12.10 Distribution by Gender
Figure 12.11 Leading Industry Players: Distribution by Number of Registered Trials
Figure 12.12 Leading Non-industry Players: Distribution by Number of Registered Trials
Figure 12.13 Distribution of by Trial Status, Trial Phase and Geography
Figure 12.14 Distribution by Geography
Figure 12.15 Distribution by Trial Status and Geography
Figure 12.16 Distribution of Enrolled Patient Population by Trial Status and Geography
Figure 13.1 AC Matrix: Pictorial Representation
Figure 13.2 AC Matrix: Positioning of Different Indications
Figure 14.1 Start-up Health Indexing: Distribution by Portfolio Strength
Figure 14.2 Start-up Health Indexing: Distribution by Pipeline Maturity
Figure 14.3 Start-up Health Indexing: Distribution by Indication Diversity
Figure 14.4 Start-up Health Indexing: Distribution by Funding Amount
Figure 14.5 Start-up Health Indexing: Distribution by Partnership Activity
Figure 14.6 Start-up Health Indexing: Analyst's Perspective
Figure 14.7 Start-up Health Indexing: Leading Companies
Figure 15.1 Diabetes: Diagnostic Limits for Plasma Glucose Levels
Figure 15.2 Non-Insulin Therapies for Diabetes
Figure 15.3 Weight Categories as per BMI Calculations
Figure 15.4 Obese Population: Distribution by Key Geographical Regions
Figure 16.1 Partnerships and Collaborations: Distribution of Cumulative Year-wise
Trend, Since 2022
Figure 16.2 Partnerships and Collaborations: Distribution of Type of Partnership
Figure 16.3 Partnerships and Collaborations: Distribution of Year and Type of Partnership, Since 2022
Figure 16.4 Partnerships and Collaborations: Distribution of Target Indication
Figure 16.5 Partnerships and Collaborations: Distribution of Therapeutic Area
Figure 16.6 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 16.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 16.8 Most Active Players: Distribution by Number of Partnerships
Figure 16.9 Partnerships and Collaborations: Local and International Deals
Figure 16.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 17.1 Funding and Investments: Cumulative Year-wise Distribution of Funding Instances, Since 2022
Figure 17.2 Funding and Investments: Cumulative Year-wise Distribution of Amount Invested (USD Million), Since 2022
Figure 17.3 Funding and Investments: Distribution by Year of Funding and Amount Invested (USD Million), Since 2022
Figure 17.4 Funding and Investments: Distribution by Type of Funding
Figure 17.5 Funding and Investments: Distribution by Year of Funding and Type of Funding, Since 2022
Figure 17.6 Funding and Investments: Distribution by Type of Funding and Amount Invested (USD Million)
Figure 17.7 Funding and Investments: Distribution by Purpose of Funding
Figure 17.8 Funding and Investments: Distribution by Target Indication
Figure 17.9 Funding and Investments: Distribution by Therapeutic Area
Figure 17.10 Funding and Investments: Distribution by Geography
Figure 17.11 Most Active Players: Distribution by Number of Instances
Figure 17.12 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 17.13 Leading Investors: Distribution by Number of Funding Instances
Figure 17.14 Funding and Investment Summary, Since 2022
Figure 18.1 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Year of Establishment
Figure 18.2 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Company Size
Figure 18.3 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Location of Headquarters
Figure 18.4 Live Biotherapeutic Products and Microbiome Contract Manufacturers:
Distribution by Scale of Operation
Figure 18.5 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Product Manufactured
Figure 18.6 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Type of Formulation
Figure 18.7 Live Biotherapeutic Products and Microbiome Contract Manufacturers: Distribution by Scale of Operation and Type of Formulation
Figure 19.1 Big Data: The Three V’s
Figure 19.2 Internet of Things: Framework
Figure 19.3 Internet of Things: Applications in Healthcare
Figure 19.4 Big Data: Google Trends Analysis
Figure 19.5 Big Data and Microbiome: Google Trends
Figure 19.6 Big Data: Key Application Areas
Figure 19.7 Big Data: Opportunities in Healthcare
Figure 19.8 Big Data: Key Benefits for Pharmaceutical and Biotechnology Products
Figure 19.9 Challenges Associated with Microbiome-related Big Data Management
Figure 20.1 Global Human Microbiome Therapeutics Market, Forecasted Estimates (till 2035) (USD Million)
Figure 20.2 Human Microbiome Market: Distribution by Type of Product
Figure 20.3 Human Microbiome Market for Therapeutics: Forecasted Estimates (till 2035) (USD Million)
Figure 20.4 Human Microbiome Market for Diagnostics: Forecasted Estimates (till 2035) (USD Million)
Figure 20.5 Human Microbiome Market for Fecal Microbiota Therapies: Forecasted Estimates (till 2035) (USD Million)
Figure 20.6 Global Human Microbiome Therapeutics Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 20.7 Global Human Microbiome Therapeutics Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 21.1 Human Microbiome Therapeutics Market: Distribution by Type of Biologic
Figure 21.2 Human Microbiome Therapeutics Market for Live Biotherapeutics: Forecasted Estimates (till 2035) (USD Million)
Figure 21.3 Human Microbiome Therapeutics Market for Others: Forecasted Estimates (till 2035) (USD Million)
Figure 22.1 Human Microbiome Therapeutics Market: Distribution by Route of Administration
Figure 22.2 Human Microbiome Therapeutics Market for Oral Route: Forecasted Estimates (till 2035) (USD Million)
Figure 22.3 Human Microbiome Therapeutics Market for Rectal Route: Forecasted
Estimates (till 2035) (USD Million)
Figure 23.1 Human Microbiome Therapeutics Market: Distribution by Drug Formulation
Figure 23.2 Human Microbiome Therapeutics Market for Capsules: Forecasted Estimates (till 2035) (USD Million)
Figure 23.3 Human Microbiome Therapeutics Market for Suspensions: Forecasted Estimates (till 2035) (USD Million)
Figure 23.4 Human Microbiome Therapeutics Market for Enemas: Forecasted Estimates (till 2035) (USD Million)
Figure 23.5 Human Microbiome Therapeutics Market for Powders: Forecasted Estimates (till 2035) (USD Million)
Figure 24.1 Human Microbiome Therapeutics Market: Distribution by Target Indication
Figure 24.2 Human Microbiome Therapeutics Market for Clostridium Difficile Infection: Forecasted Estimates (till 2035) (USD Million)
Figure 24.3 Human Microbiome Therapeutics Market for Necrotizing Enterocolitis: Forecasted Estimates (till 2035) (USD Million)
Figure 24.4 Human Microbiome Therapeutics Market for Irritable Bowel Syndrome: Forecasted Estimates (till 2035) (USD Million)
Figure 24.5 Human Microbiome Therapeutics Market for Acute Graft Versus Host Disease: Forecasted Estimates (till 2035) (USD Million)
Figure 25.1 Human Microbiome Therapeutics Market: Distribution by Target Therapeutic Area
Figure 25.2 Human Microbiome Therapeutics Market for Infectious Diseases: Forecasted Estimates (till 2035) (USD Million)
Figure 25.3 Human Microbiome Therapeutics Market for Gastrointestinal Disorders: Forecasted Estimates (till 2035) (USD Million)
Figure 25.4 Human Microbiome Therapeutics Market for Rare Disorders: Forecasted Estimates (till 2035) (USD Million)
Figure 26.1 Human Microbiome Therapeutics Market: Distribution by Geographical Regions
Figure 26.2 Human Microbiome Therapeutics Market in North America: Forecasted Estimates (till 2035) (USD Million)
Figure 26.3 Human Microbiome Therapeutics Market in the US: Forecasted Estimates (till 2035) (USD Million)
Figure 26.4 Human Microbiome Therapeutics Market in Canada: Forecasted Estimates (till 2035) (USD Million)
Figure 26.5 Human Microbiome Therapeutics Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Figure 26.6 Human Microbiome Therapeutics Market in Germany: Forecasted Estimates (till 2035) (USD Million)
Figure 26.7 Human Microbiome Therapeutics Market in the UK: Forecasted Estimates (till 2035) (USD Million)
Figure 26.8 Human Microbiome Therapeutics Market in Spain: Forecasted Estimates (till 2035) (USD Million)
Figure 26.9 Human Microbiome Therapeutics Market in France: Forecasted Estimates (till 2035) (USD Million)
Figure 26.10 Human Microbiome Therapeutics Market in Italy: Forecasted Estimates (till 2035) (USD Million)
Figure 26.11 Human Microbiome Therapeutics Market in Rest of Europe: Forecasted Estimates (till 2035) (USD Million)
Figure 26.12 Human Microbiome Therapeutics Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Million)
Figure 26.13 Human Microbiome Therapeutics Market in China: Forecasted Estimates (till 2035) (USD Million)
Figure 26.14 Human Microbiome Therapeutics Market in Australia: Forecasted Estimates (till 2035) (USD Million)
Figure 26.15 Human Microbiome Therapeutics Market in Latin America: Forecasted Estimates (till 2035) (USD Million)
Figure 26.16 Human Microbiome Therapeutics Market in Brazil: Forecasted Estimates (till 2035) (USD Million)
Figure 26.17 Human Microbiome Therapeutics Market in Middle East and North Africa: Forecasted Estimates (till 2035) (USD Million)
Figure 26.18 Human Microbiome Therapeutics Market in Israel: Forecasted Estimates (till 2035) (USD Million)
Figure 26.19 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 26.20 Market Movement Analysis: Geographical Regions
Figure 27.1 Global Human Microbiome Diagnostics Market, Forecasted Estimates (till 2035) (USD Million)
Figure 27.2 Global Human Microbiome Diagnostics Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 27.3 Global Human Microbiome Diagnostics Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 28.1 Human Microbiome Diagnostics Market: Distribution by Target Indication
Figure 28.2 Human Microbiome Diagnostics Market for Diabetes Mellitus: Forecasted Estimates (till 2035) (USD Million)
Figure 28.3 Human Microbiome Diagnostics Market for Irritable Bowel Syndrome: Forecasted Estimates (till 2035) (USD Million)
Figure 28.4 Human Microbiome Diagnostics Market for Irritable Bowel Disease: Forecasted Estimates (till 2035) (USD Million)
Figure 28.5 Human Microbiome Diagnostics Market for Colorectal Cancer: Forecasted Estimates (till 2035) (USD Million)
Figure 29.1 Human Microbiome Diagnostics Market: Distribution by Target Therapeutic Area
Figure 29.2 Human Microbiome Diagnostics Market for Gastrointestinal Disorders: Forecasted Estimates (till 2035) (USD Million)
Figure 29.3 Human Microbiome Diagnostics Market for Metabolic Disorders: Forecasted Estimates (till 2035) (USD Million)
Figure 29.4 Human Microbiome Diagnostics Market for Oncological Disorders: Forecasted Estimates (till 2035) (USD Million)
Figure 30.1 Human Microbiome Diagnostics Market: Distribution by Geographical Regions
Figure 30.2 Human Microbiome Diagnostics Market in North America: Forecasted Estimates (till 2035) (USD Million)
Figure 30.3 Human Microbiome Diagnostics Market in the US: Forecasted Estimates (till 2035) (USD Million)
Figure 30.4 Human Microbiome Diagnostics Market in Canada: Forecasted Estimates (till 2035) (USD Million)
Figure 30.5 Human Microbiome Diagnostics Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Figure 30.6 Human Microbiome Diagnostics Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Million)
Figure 30.7 Human Microbiome Diagnostics Market in China: Forecasted Estimates (till 2035) (USD Million)
Figure 30.8 Human Microbiome Diagnostics Market in India: Forecasted Estimates (till 2035) (USD Million)
Figure 30.9 Human Microbiome Diagnostics Market in Japan: Forecasted Estimates (till 2035) (USD Million)
Figure 30.10 Human Microbiome Diagnostics Market in Latin America: Forecasted Estimates (till 2035) (USD Million)
Figure 30.11 Human Microbiome Diagnostics Market in Brazil: Forecasted Estimates (till 2035) (USD Million)
Figure 30.12 Human Microbiome Diagnostics Market in Middle East and North Africa: Forecasted Estimates (till 2035) (USD Million)
Figure 30.13 Human Microbiome Diagnostics Market in Saudi Arabia: Forecasted Estimates (till 2035) (USD Million)
Figure 30.14 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 30.15 Market Movement Analysis: Geographical Regions
Figure 31.1 Global Human Microbiome Fecal Microbiota Therapies Market, Forecasted
Estimates (till 2035) (USD Million)
Figure 31.2 Global Human Microbiome Fecal Microbiota Therapies Market, Forecasted Estimates (till 2035): Conservative Scenario (USD Million)
Figure 31.3 Global Human Microbiome Fecal Microbiota Therapies Market, Forecasted Estimates (till 2035): Optimistic Scenario (USD Million)
Figure 32.1 Human Microbiome Fecal Microbiota Therapies Market: Distribution by Geographical Regions
Figure 32.2 Human Microbiome Fecal Microbiota Therapies Market in North America: Forecasted Estimates (till 2035) (USD Million)
Figure 32.3 Human Microbiome Fecal Microbiota Therapies Market in Europe: Forecasted Estimates (till 2035) (USD Million)
Figure 32.4 Human Microbiome Fecal Microbiota Therapies Market in Asia-Pacific: Forecasted Estimates (till 2035) (USD Million)
Figure 32.5 Human Microbiome Fecal Microbiota Therapies Market in Latin America: Forecasted Estimates (till 2035) (USD Million)
Figure 32.6 Human Microbiome Fecal Microbiota Therapies Market in Middle East and North Africa: Forecasted Estimates (till 2035) (USD Million)
Figure 32.7 Penetration Growth (P-G) Matrix: Geographical Regions
Figure 32.8 Market Movement Analysis: Geographical Regions
Figure 43.1 Concluding Remarks: Human Microbiome Therapeutics Market Landscape
Figure 43.2 Concluding Remarks: Human Microbiome Diagnostics and Screening / Profiling Tests Market Landscape
Figure 43.3 Concluding Remarks: Human Microbiome Fecal Microbiota Therapies Market Landscape
Figure 43.4 Concluding Remarks: Clinical Trial Analysis
Figure 43.5 Concluding Remarks: Start-up Health Indexing
Figure 43.6 Concluding Remarks: Partnerships and Collaborations
Figure 43.7 Concluding Remarks: Funding and Investments
Figure 43.8 Concluding Remarks: Human Microbiome Therapeutics Market Forecast
Figure 43.9 Concluding Remarks: Human Microbiome Diagnostics Market Forecast
Figure 43.10 Concluding Remarks: Human Microbiome Fecal Microbiota Therapies Market Forecast